The Characteristics of Patients With COVID‐19–Associated Pediatric Vasculitis: An International, Multicenter Study
Authors' conclusion
Our findings suggest that children with COVID-19-associated IgAV/HSP experience a more severe disease course compared to pediatric IgAV/HSP patients before the pandemic.
Study context
- Population
- Children <18 years at vasculitis onset with evidence of vasculitis and SARS-CoV-2 exposure ≤3 months before onset, excluding multisystem inflammatory syndrome in children (MIS-C); 14 centres, 6 countries41 patients · 14 centres · 6 countries
- Participants
- 30 vs 159
- Exposure
- COVID-19-associated pediatric IgAV/HSP vs pre-pandemic pediatric IgAV/HSP cohort
- COVID-19-associated IgAV/HSPn = 30
- Pre-pandemic IgAV/HSPn = 159reference
- Outcome
- Characteristics, treatment and outcomes of COVID-19-associated pediatric vasculitis
Methodological detailsmulticentre, international, comparison with pre-pandemic cohort
- Multicentre
- International
- Comparison with pre-pandemic cohort
Main finding
As reported in the abstract
- Median age
- 8.3 years
- Male to female ratio
- 1.3
- IgAV/HSP (most frequent subtype), n
- 30
- Median time from SARS-CoV-2 exposure to vasculitis onset
- 13 days
- Skin involvement
- 92.7%
- Gastrointestinal involvement
- 61%
- Received GC
- 68.3%
- Also received additional immunosuppressive drugs
- 14.6%
Observational data: associations, not effects.
Further findings
Fever
P < 0.001
Renal involvement
P = 0.002
Recovery without treatment
P = 0.002
Complete recovery
P = 0.002
Manifestations in COVID-19-associated IgAV/HSP subset
- Gastrointestinal involvement
- 18 (60%)
- Renal involvement
- 13 (43.3%)
- Skin manifestations in all patients
Original publication
The Characteristics of Patients With COVID‐19–Associated Pediatric Vasculitis: An International, Multicenter Study. Arthritis Rheumatol. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →